In this episode, the experts assess the latest data on targeted therapy for KRAS G12C-mutated NSCLC, including the first phase III data on targeted therapy. Hear expert opinions of how these results may influence clinical practice.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
